We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Epigenetic Biomarker Predicts Outcome of Childhood Brain Cancer

By Gerald M. Slutzky, PhD
Posted on 07 Dec 2016
Print article
Image: A micrograph of an ependymoma (Photo courtesy of Wikimedia Commons).
Image: A micrograph of an ependymoma (Photo courtesy of Wikimedia Commons).
Cancer researchers have identified a biomarker that predicts the likely outcome of the childhood brain cancer posterior fossa ependymoma (PF).

This type of cancer is characterized by tumors found largely in the hind brain (consisting of the cerebellum, pons, and the brainstem) of children. The prognosis of these tumors does not necessarily correlate with clinical characteristics or even tumor grade, and there are no recurrent genetic mutations that can be used to classify these tumors.

An international team of researchers led by investigators at Children's Hospital Los Angeles (CA, USA) and the University of Michigan (Ann Arbor, USA) searched for other markers that might be used to classify PF tumors. To this end, they focused on the epigenetics of ependymoma tumors, specifically on the methylation pattern of histones in the tumor cells.

The investigators reported that most PF tumors lacked methylation of histone H3. Approximately 80% exhibited loss of the H3K27me3 biomarker, while 20% of tumors retained H3K27me3. By linking H3 methylation to clinical outcomes, the investigators showed that H3K27me3 immunostaining served as a biomarker for poor prognosis and delineated radiologically invasive tumors, suggesting that reduced H3K27me3 may be a prognostic indicator in PF ependymomas.

"Detection of H3K27me3 by immunohistochemical staining is a widely available and cost effective surrogate molecular marker. This test can be readily implemented in most departments of pathology and provides a much-needed tool to risk stratify and identify ependymoma patients who would potentially benefit from epigenetic therapies," said contributing author Dr. Alexander R. Judkins, head of pathology and laboratory medicine at Children's Hospital Los Angeles.

"By demonstrating the epigenetic mechanism - that we theorize likely goes awry during brain development - we will be better able to identify these tumors, determine a more accurate prognosis and - importantly -perhaps develop better therapeutic options," said senior author Dr. Sriram Venneti, professor of pathology at the University of Michigan.

The study was published in the November 23, 2016, online edition of the journal Science Translational Medicine.

Related Links:
Children's Hospital Los Angeles
University of Michigan
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.